An estimated 10 percent of the U.S. population has been diagnosed with diabetes, a number that may be apt to rise in the near future. Peculiarly, the reason for that may have to do with the pandemic. Since the pandemic’s onset, researchers have found a link between contracting COVID-19 and an increased risk of receiving a diabetes diagnosis months later — especially in children, as one study showed that COVID-19 receptors can reduce insulin levels and kill pancreatic beta cells.
While there is still much to learn about the connection between COVID-19 and diabetes, a potential wave of diabetes infections comes at an unprecedented time for the disease — perhaps when a cure is on the horizon.
Yes, not treatment, but cure. Long considered a holy grail of sorts for medicine, diabetes — one of the most expensive, consuming and pervasive chronic diseases — is inching towards a cure, to the extent that researchers are actually openly using that word.
“There’s a lot of exciting research underway focused on curing Type 1 diabetes,” Dr. Marlon Pragnell, vice president of research and science at the American Diabetes Association, told Salon.
In November 2021, news broke that Brian Shelton, a 64-year-old man in Ohio, might be the first person to ever be cured of type 1 diabetes. Shelton was part of a clinical trial by Vertex Pharmaceuticals, in which participants individually receive an infusion of stem cells that in turn create the insulin-producing pancreas cells the body lacks with Type 1 diabetes. In total, the study will take five years and only involve 17 people with severe cases of Type 1 diabetes.
In order to maintain safe levels of glucose in the blood, beta cells in the pancreas produce insulin. These are known as islet cells. However, when a person has Type 1 diabetes, the beta cells are destroyed by a person’s own immune system. In turn, those with Type 1 diabetes must monitor their own insulin levels, and inject themselves with insulin as needed to digest glucose.
RELATED: The science of sugar substitutes
The Vertex Pharmaceuticals therapy works by replacing insulin-producing cells that have been destroyed with stem cells that convert into insulin-secreting islet cells.
There are still many unknowns with the trial, such as whether there are adverse effects, and if the therapy lasts a lifetime or needs to be repeated. The trial is also experimenting with dosage and way in which the therapy is administered.
“We’re evaluating multiple approaches to deliver the insulin-producing cells, including a transplant approach that requires immunosuppression (the VX-880 program), and a device approach that is intended to protect the transplanted cells from the immune system,” Heather Nichols, a spokesperson for Vertex Pharmaceuticals, told Salon. Nichols said they hoped to apply for an investigational new drug. “Both approaches use our proprietary, fully differentiated, insulin-producing islet cells,” she continued.
Want more health and science stories in your inbox? Subscribe to Salon’s weekly newsletter The Vulgar Scientist.
The initial results from Shelton shocked diabetes researchers. “It is a remarkable result,” Dr. Peter Butler, a diabetes expert at the University of California, Los Angeles, told The New York Times in November. “To be able to reverse diabetes by giving them back the cells they are missing is comparable to the miracle when insulin was first available 100 years ago.”
The last century has certainly been one of hope for people with diabetes, as evidence suggests that one of the types of diabetes mellitus — which refer to the three types (Type 1, Type 2 and gestational diabetes) — existed way back in the 16th century, when the first symptoms of diabetes were documented. An Egyptian physician named Hesy-Ra wrote about a mysterious disease that included frequent urination, and caused emaciation. From typhoid to scurvy, many diseases from that time period now have cures — but not diabetes. While diabetes can be treated and controlled, and some people may go into remission, no cure currently exists. But thanks to this new treatment using stem cells that produces insulin, a new cure could be possible within the next decade.
Still, there still are a few quirks to figure out before stem cell therapy is accessible to everyone. And just because positive results have been reported in one trial participant, as Nichols said, dosing and the way the treatment is administered will differ in the next 15 participants.
“It’s difficult to say how close we are to a cure, but the beta cell therapy approaches are certainly very exciting,” Pragnell said, adding that previously, islet transplants from deceased donors have shown to achieve “insulin independence.” Yet there are significant barrier in finding deceased donors available to meet that demand — a problem stem-cell therapy can solve. “The potential to grow large quantities of insulin-producing cells in the laboratory could solve this problem,” Pragnell noted.
Pragnell said if researchers are able to demonstrate that these stem-cell approaches are both safe and lead to long-term insulin independence, it would be “transformational.”
“There would still be a need for immunosuppressive therapy, but it is conceivable that future gene editing approaches may enable researchers to switch off genes that may cause rejection and/or insert genes that promote the body’s acceptance of the transplanted cells,” Pragnell said.
Read more on the diabetes:
